![Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers: Cell Reports Medicine Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers: Cell Reports Medicine](https://www.cell.com/cms/attachment/f0a3a665-a68f-4889-a167-d25682944a98/fx1.jpg)
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers: Cell Reports Medicine
![Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer | npj Precision Oncology Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer | npj Precision Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41698-024-00536-7/MediaObjects/41698_2024_536_Fig1_HTML.png)
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer | npj Precision Oncology
![PDF) Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer PDF) Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer](https://i1.rgstatic.net/publication/378360460_Selpercatinib_combination_with_the_mitochondria-targeted_antioxidant_MitoQ_effectively_suppresses_RET-mutant_thyroid_cancer/links/65d600adadc608480ade67fb/largepreview.png)
PDF) Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET–mutant thyroid cancer
![Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer | Future Oncology Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer | Future Oncology](https://www.futuremedicine.com/pb-assets/Digital_Assets/Infographics/Thumbnails/FON-2020-0935_tb-1604581747127.jpg)
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer | Future Oncology
![Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers | Eli Lilly and Company Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers | Eli Lilly and Company](https://investor.lilly.com/sites/g/files/knoqqb54341/themes/site/nir_pid1228/dist/images/IR-Carousel-woman-testing-04062020-Research15033-5048-01_2.jpg)
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers | Eli Lilly and Company
Written By: Joshua Nubla, PharmD NCODA Positive Quality Intervention: Selpercatinib (Retevmo®) Management Description: This PQI
![Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - ScienceDirect Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666379123005499-gr2.jpg)